New Triple-Drug attack on tough liver cancer halted before start
NCT ID NCT06608940
Summary
This study aimed to test a new three-drug combination for advanced liver cancer that cannot be removed by surgery. It planned to add an experimental drug called BC3402 to a standard two-drug immunotherapy regimen to see if it was safe and more effective. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.